Liquid biopsies: are insurers keeping pace with advancements in cancer care?

Written by Ilana Landau, Editor

New research explores insurance coverage policy trends for circulating tumor DNA (ctDNA) panel tests, which can represent a key aspect to the delivery and monitoring of targeted cancer therapies. New research, led by investigators from the University of California, San Francisco and City of Hope (both CA, USA), explores insurance policy coverage trends for circulating tumor DNA (ctDNA) panel tests for cancer indications – commonly referred to as ‘liquid biopsies’ – which can represent a key aspect to the delivery and monitoring of targeted cancer therapies. Use of blood-based ctDNA tests to help select targeted cancer therapies and monitor non-responding...

To view the full article, please register now for access

It's completely free